Skip to main content
Premium Trial:

Request an Annual Quote

Natera Prospera Heart

Natera has launched its Prospera Heart transplant assessment test for heart transplant recipients. The Prospera test uses Natera's core SNP-based massively multiplexed PCR technology to identify allograft rejection non-invasively and with high precision and accuracy, without the need for prior donor or recipient genotyping. The test works by measuring the fraction of donor-derived cell-free DNA in the recipient's blood. It may be used by physicians considering the diagnosis of active rejection, helping to rule in or out this condition when evaluating the need for diagnostic testing or the results of an invasive biopsy.

The Prospera test has been clinically and analytically validated for performance regardless of donor relatedness, rejection type, and clinical presentation, Natera said.